ArticlePatient preference and adherence2012
Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials.
Article in Patient preference and adherence, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies.Orphanet journal of rare diseases · 2018Pooled it
- Clinical management of coronary heart disease in hypertension : practical recommendations from the Italian Society of Hypertension (SIIA).High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2013Guideline
- Losartan-induced Angioedema: A Case Report and Review of Literature.Journal of community hospital internal medicine perspectives · 2026Article
- Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease.International journal of molecular sciences · 2022Review
- Telmisartan-induced angioedema: A rare clinical finding.Journal of family medicine and primary care · 2022Article
- Scaling up effective treatment of hypertension-A pathfinder for universal health coverage.Journal of clinical hypertension (Greenwich, Conn.) · 2019Article
- Recommended treatment protocols to improve management of hypertension globally: A statement by Resolve to Save Lives and the World Hypertension League (WHL).Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
- Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.Pharmacological research · 2017Review
- Angioedema due to fixed dose combination of telmisartan plus ramipril.Journal of pharmacology & pharmacotherapeutics · 2014Article
- Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.Vascular health and risk management · 2014Review
- Visual hallucinations related to angiotensin-converting enzyme inhibitor use: case reports and review.Journal of clinical hypertension (Greenwich, Conn.) · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telmisartan is indicated for the prevention of cardiovascular events in high-risk patients, based on comparable efficacy to the angiotensin-converting enzyme (ACE) inhibitor, ramipril, in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET(®)) trial. However, tolerability must be considered when selecting treatments. This analysis compared the tolerability of telmisartan and ACE inhibitors using data pooled from 12 comparative, randomized studies involving 2564 telmisartan-treated patients and 2144 receiving ACE inhibitors (enalapril, lisinopril, or ramipril). Incidence rates of adverse events for the combined ACE inhibitor treatments and for telmisartan were similar (42.8% vs 43.9%, respectively) as were the rates of serious adverse events (1.8% vs 1.7% for telmisartan, respectively). Patients receiving ACE inhibitors had more cough (8.6% vs 2.6% with telmisartan, P < 0.0001). Results were similar irrespective of age, gender, or ethnicity. The adverse event of angioedema was observed in four patients (0.2%) receiving ACE inhibitors versus none with telmisartan (P = 0.043). There were small, numerical differences in serious adverse events. A total of 107 patients (5.0%) receiving ACE inhibitors and 93 patients (3.6%) receiving telmisartan discontinued treatment because of adverse events (P = 0.021); of these, 32.7% and 5.4%, respectively, were discontinuations due to cough (relative risk reduction of 88% [P < 0.0001] with telmisartan). Telmisartan and ACE inhibitors produced comparable blood pressure reductions at marketed doses. Telmisartan and ACE inhibitors are suitable for the prevention of cardiovascular events in high-risk patients, but telmisartan is better tolerated, particularly with regard to cough.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.